The Journal of Urology
Volume 181, Issue 3 , Pages 956-962 , March 2009

Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial

  • Ian M. Thompson

      Affiliations

    • University of Texas Health Science Center at San Antonio, San Antonio, Texas
    • Corresponding Author InformationCorrespondence: Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229 (telephone: 210-567-5643; FAX: 210-567-6868)
    • Financial interest and/or other relationship with Veridex, Mission and AstraZeneca.
    • ,
  • Catherine M. Tangen

      Affiliations

    • The Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Jorge Paradelo

      Affiliations

    • The Kansas City Community Clinical Oncology Program, Kansas City, Missouri
    • ,
  • M. Scott Lucia

      Affiliations

    • The University of Colorado Health Science Center, Denver, Colorado
    • ,
  • Gary Miller

      Affiliations

    • The University of Colorado Health Science Center, Denver, Colorado
    • Deceased.
    • ,
  • Dean Troyer

      Affiliations

    • University of Texas Health Science Center at San Antonio, San Antonio, Texas
    • ,
  • Edward Messing

      Affiliations

    • The James P. Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, New York
    • ,
  • Jeffrey Forman

      Affiliations

    • Wayne State University School of Medicine, Detroit, Michigan
    • ,
  • Joseph Chin

      Affiliations

    • University of Western Ontario, Department of Surgical Oncology, London, Ontario
    • ,
  • Gregory Swanson

      Affiliations

    • University of Texas Health Science Center at San Antonio, San Antonio, Texas
    • ,
  • Edith Canby-Hagino

      Affiliations

    • Wilford Hall Medical Center, San Antonio, Texas
    • ,
  • E. David Crawford

      Affiliations

    • The University of Colorado Health Science Center, Denver, Colorado

Received 15 September 2008

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71
  2. Underwood W, Jackson J, Wei JT, Dunn R, Baker E, Demonner S, et al. Racial treatment trends in localized/regional prostate carcinoma: 1992–1999. Cancer. 2005;103:538
  3. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977
  4. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, et al. The contemporary management of prostate cancer in the United States: lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry. J Urol. 2004;171:1393
  5. Klein EA, Bianco FJ, Serio AM, Eastham JA, Kattan MW, Pontes JE, et al. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol. 2008;179:2212
  6. Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler T, Maru N, et al. Do margins matter? (The prognostic significance of positive surgical margins in radical prostatectomy specimens). J Urol. 2008;179:S47
  7. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer (A randomized clinical trial). JAMA. 2006;296:2329
  8. Moinpour CM, Hayden KA, Unger JM, Thompson IM, Redman MW, Canby-Hagino ED, et al. Health related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol. 2008;26:112
  9. Kaplan EL, Meier P. Nonparametric estimation with incomplete observations. J Am Stat Assoc. 1958;53:457
  10. Cooperberg M, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005;23:8146
  11. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513
  12. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502
  13. Pietrow PK, Parekh DJ, Smith JA, Shyr Y, Cookson MS. Health related quality of life assessment after radical prostatectomy in men with prostate specific antigen only recurrence. J Urol. 2001;166:2286
  14. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250
  15. Van der Kwast TH, Bolla M, Van Poppel H, Cangh PV, Vekemans K, Da Pozzo L, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol. 2007;25:4178
  16. Kondylis FI, Moriarty RP, Bostwick D, Schellhammer PF. Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias. J Urol. 2003;170:1189
  17. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325
  18. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035
  19. Slawin KM. Radiation therapy after radical prostatectomy: why patience is a virtue! The case for salvage radiation therapy. Rev Urol. 2002;4:90

 Study received approval from individual institutional review boards of the participating institutions.

 Supported by Public Health Service Cooperative Agreement grants awarded by the National Cancer Institute, Department of Health and Human Services: CA38926, CA32102, CA14028, CA58416, CA58658, CA42777, CA27057, CA46136, CA35431, CA58882, CA12644, CA58861, CA35090, CA37981, CA76429, CA04919, CA76132, CA35119, CA35178, CA35176, CA46282, CA67575, CA45377, CA46113, CA74647, CA35261, CA049020, CA20319, CA76447, CA58723, CA12213, CA22433, CA46441, and by the National Cancer Institute of Canada Grant PR-2.

PII: S0022-5347(08)03059-0

doi: 10.1016/j.juro.2008.11.032

The Journal of Urology
Volume 181, Issue 3 , Pages 956-962 , March 2009

Article Tools

* Image Usage & Resolution